Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maia Biotechnology Inc (MAIA)

Maia Biotechnology Inc (MAIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,438
  • Shares Outstanding, K 37,032
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,250 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8700 +37.93%
on 11/20/25
1.4600 -17.81%
on 12/01/25
+0.0700 (+6.19%)
since 11/05/25
3-Month
0.8700 +37.93%
on 11/20/25
1.9700 -39.09%
on 10/07/25
-0.3400 (-22.08%)
since 09/05/25
52-Week
0.8700 +37.93%
on 11/20/25
2.7400 -56.20%
on 05/02/25
-0.7800 (-39.39%)
since 12/05/24

Most Recent Stories

More News
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies...

MAIA : 1.2000 (unch)
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 ...

MAIA : 1.2000 (unch)
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation

Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) --...

MAIA : 1.2000 (unch)
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)...

MAIA : 1.2000 (unch)
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”,...

MAIA : 1.2000 (unch)
MAIA Biotechnology Announces Private Placement Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

MAIA : 1.2000 (unch)
MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies...

MAIA : 1.2000 (unch)
MAIA Biotechnology Adopts New Digital Asset Strategy

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

MAIA : 1.2000 (unch)
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE)...

MAIA : 1.2000 (unch)
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END

CELC : 105.63 (-0.23%)
GTBP : 0.6094 (-3.24%)
IOBT : 0.6967 (+2.74%)
LPTX : 2.0500 (+368.57%)
MAIA : 1.2000 (unch)

Business Summary

MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers....

See More

Key Turning Points

3rd Resistance Point 1.2832
2nd Resistance Point 1.2465
1st Resistance Point 1.2233
Last Price 1.2000
1st Support Level 1.1634
2nd Support Level 1.1267
3rd Support Level 1.1035

See More

52-Week High 2.7400
Fibonacci 61.8% 2.0257
Fibonacci 50% 1.8050
Fibonacci 38.2% 1.5843
Last Price 1.2000
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar